Background. We examined trends in the incidence of the 3 AIDS-defining cancers (ADC)
Introduction
The three AIDS-defining cancers (ADC) namely Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL) and cervical cancer were added to the list of AIDS-defining conditions by the Centers for Disease Control and Prevention [1] because of their association with immunodeficiency [2] [3] [4] [5] . The three ADC are known to be associated with viral infections [6] , namely human herpes virus 8 (HHV-8) for KS, Epstein-Barr virus (EBV) for most cases of NHL in HIV-infected patients and human papilloma virus (HPV) for cervical cancer. Compared to the general population, a meta-analysis of studies conducted mainly in the pre-combined antiretroviral therapy (cART) era suggested that the risk in HIV-infected patients was 3640-fold higher for KS, 77-fold higher for NHL and 6-fold higher for cervical cancer [7] .
Since the advent of cART in 1996, several studies have shown a large fall in the incidence of KS and NHL [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , while the results for cervical cancer are heterogeneous [9, 11, 12, 16, 17] , mainly owing to the small number of cases. These studies did not extend beyond the year 2006, and some of them involved only patients with AIDS rather than all patients living with HIV [9, 11, 15, 17] . The number of HIV-infected patients with CD4 cell counts above 500 cells/mm 3 has increased since the advent of cART, and it is therefore interesting to investigate whether the elevated risk of ADC persists in patients with restored immunity.
Age-related comorbidities have been found to occur much earlier in patients infected with HIV than in uninfected individuals [18, 19] . However, Shiels et al. [20] , studying age at diagnosis of non AIDS-defining cancers, with adjustment for the difference in age distribution between patients with AIDS and the general population, found that differences in median age at diagnosis were modest and that few of them were statistically significant. This "premature aging" hypothesis has not been tested for ADC.
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A c c e p t e d M a n u s c r i p t 5 The aim of this study was to evaluate long-term trends in the incidence of each ADC among patients enrolled in the French Hospital Database on HIV (FHDH ANRS CO4), one of the largest cohorts of HIV-infected patients, by comparison with the general population in France during the period 1992-2009. We also estimated standardized incidence ratios (SIR), both overall and for the subset of patients with controlled viral load and restored immunity on cART. Differences in age at ADC diagnosis between the HIV-infected and general populations were also evaluated. 
METHODS

Study population
Statistical methods
The study was divided into pre-cART (1992) (1993) (1994) (1995) (1996) , early-cART (1997) (1998) (1999) (2000) , intermediate-cART 
RESULTS
Patients' characteristics
This analysis included 99309 HIV1-infected patients contributing to 687336 PY and corresponding to a mean follow-up of 6.9 years ( Figure 2 ). The patients' characteristics at entry in each calendar period are shown in Table 1 . Median age increased across the study periods. The A c c e p t e d M a n u s c r i p t 8 proportion of patients with HIV RNA ≤500 copies/ml increased from 24% in the early-cART period to 54% in the late-cART period and that of patients with CD4 cell count of ≥500/mm 3 from 20% in the pre-cART period to 37% in the late-cART period, in line with the increase in the proportion of patients on cART during the overall study period. We excluded 2781 prevalent cases of KS, 753 prevalent cases of NHL and 50 prevalent cases of cervical cancer ( Figure 2 ).
Between 1992 and 2009, 5890 incident ADC were reported, comprising 3366 cases of KS, 2344 cases of NHL and 180 cases of cervical cancer. The majority of cases (n= 3265, 55%) occurred in the pre-cART, followed by 1015 cases (17%) in the early-cART, 807 cases (14%) in the intermediate-cART, and 803 cases (14%) in the late-cART period.
Trends in the incidence of ADC and comparison with the general population
Age-and sex-standardized IRs for each ADC in the HIV-infected and general populations are shown in Figure 3 , and the corresponding excess IRs relative to the general population are shown in Table 2 . Regarding KS (Figure 3a) , HIV-infected men who have sex with men (MSM) continued to have the highest risk during all the calendar periods. The incidence of KS fell significantly between the pre-cART and cART periods (p<0.0001), and continued to fall significantly in the cART era (p<0.0001), except among HIV-infected women (p=0.1560).
Relative to the general population, the incidence of KS in the HIV-infected population was higher in all sex and HIV transmission groups during all the cART periods. The excess IR for KS during the late-cART period was 286 cases per 100000 PY among HIV-infected MSM, 105 cases per 100000 PY among other HIV-infected men, and 59 cases per 100000 PY among HIV-infected women.
The incidence of NHL among HIV-infected patients (Figure 3b ) fell significantly across the calendar periods (p<0.0001) and also over the cART period (p<0.0001). The incidence in both by Jules Levin on August 13, 2013 http://cid.oxfordjournals.org/ Downloaded from periods. In the late-cART period, the excess IR for NHL was 159 cases per 100000 PY in HIVinfected men and 87 cases per 100000 PY in HIV-infected women.
The incidence of cervical cancer (Figure 3c ) fell significantly both among HIV-infected women and in the general female population across the calendar periods (p<0.0001). The decline among HIV-infected women was also significant during the cART period (p=0.0005). The incidence of cervical cancer was higher in HIV-infected women than in the general population, with an excess IR of 51 cases per 100000 PY in the late-cART period.
Standardized incidence ratios compared to the general population
SIRs calculated according to sex, the HIV transmission group and the calendar period are shown in Table 3 . Although a 2.5-fold decline in KS was observed during the study period, the relative risk (RR) remained >300 during all the calendar periods. A marked decline (13-fold) in NHL was observed during the study period, but the RR remained 9-fold higher in HIV-infected patients than in the general population during the late-cART period. The RR for cervical cancer declined 2-fold during the study period, but remained 5-fold higher in HIV-infected patients than in the general population in the late-cART period. Compared with the general population, patients on cART with CD4 cell counts ≥500/mm Age at cancer diagnosis HIV-infected patients were diagnosed with ADC much earlier than the general population, with a median difference ranging from -13 years for cervical cancer to -17 years for KS and -31 years for NHL. After adjusting for the difference in age and sex structure between the two populations, the "real" difference was smaller but remained significant for KS (-2.2 years), cervical cancer (-3.2 years), and NHL (-11.3 years) ( Table 5 ).
DISCUSSION
Even if the incidence of the three ADC among HIV-infected patients in France fell between the pre-cART and cART periods and continued to decline during the cART period, the risks remained significantly higher than in the general population during all the calendar periods.
Patients with restored immunity for at least 2 years and controlled viral load on cART still had a strongly elevated risk of KS (35-fold), while the risk of NHL was similar to that of the general population. Age at KS and cervical cancer diagnosis was only slightly different between HIVinfected and general populations (-2 and -3 years respectively), while the difference was more marked for NHL (-11 years).
The main strengths of this study are the large number of HIV-infected patients included and the large number of incident cancers recorded in each calendar period. This allowed us to estimate IRs and SIRs separately for each period and each cancer. As summarized by Chaturvedi et al.
[27], in most instances, the SIR reasonably approximates the RR. But when HIV prevalence is high and/or cancer incidence in HIV-infected patients relative to non-infected persons is high, the SIR tends to underestimate the RR. This could have been the case for KS which is rare among individuals not infected with HIV. However, because there are no cancer registries in the French Between the pre-and early-cART periods [9-12, 14-17, 29] and also during the cART period [9-12, 14, 16, 17] , most studies have shown a fall in the incidence of KS and NHL. This was also the case in our study, where the incidence of KS and NHL continued to decline until 2009. As previously showed [8] , the elevated incidence of KS among HIV-infected women is likely due to the high proportion of women of sub-Saharan origin (26%), who are more at risk of KS. Indeed, in 2005-2009, the incidence of KS in HIV-infected women of sub-Saharan origin was 105.0 (63.6-146.5) per 100000 PY, while the incidence in other HIV-infected women was 36.0 (19.5-52.5) per 100000 PY. For cervical cancer, although most previous studies, which included limited numbers of cases (from 8 to 74), showed no change in the incidence [9, 11, 12, 15, 16] , a study with 1276 cases [17] showed a decline among women with AIDS between 1991 and 2005. In the current study, which included all women infected with HIV and not only those with AIDS, and analyzed a large number of cases (n=180) with lengthy follow-up, the incidence of cervical cancer also declined over time.
The comparison of SIR values between different studies can be problematic as SIR estimation is not based on a common standard. Indeed, SIR values vary with the relative sizes of the different strata that compose the study population, such as sex, age and the transmission group [13, 30] . However, as in other studies [12, 13, 15, 16 , 31], we observed a higher risk for all ADCs among HIV-infected patients compared to the general population during all the calendar periods.
Furthermore, despite the decline in the RRs over time, the risk of the three ADC remained higher than in the general population during the late-cART period (300-fold for KS, 9-fold for NHL and This illustrates the fact that, in addition to the RR, it is important to take the absolute risk into account. In the study population, the median CD4 cell count rose from 259/mm cell counts ≥500/mm 3 compared to a group of HIV-uninfected individuals, after adjustment for several cancer risk factors [4] . Immune restoration was defined differently in the current analysis: instead of the current CD4 cell count, we used a continuous period of at least 2 years with high CD4 cell counts. The difference in the definition of the immune restoration could be an explanation for the different results observed in the two studies.
The younger age at ADC diagnosis among HIV-infected patients compared to the general population may be linked to 3 non-exclusive factors: (1) an earlier acquisition of oncogenic virus infection (HHV-8, EBV and HPV), (2) a closer medical surveillance of HIV-infected patients, leading to an earlier diagnosis, and/or (3) a specific effect of HIV infection. Due to the small difference in the age at diagnosis of KS (-2 years) and cervical cancer (-3 years), the third factor is not necessary to explain our results. In the case of NHL, the much larger difference (-11 years) cannot be explained only by the first 2 factors.
In conclusion, the increase of cART use and CD4 cell counts was associated with a further decline in the risk of AIDS-defining cancers, even for the cervical cancer, during the cART period. However, the risk remained higher than in the general population, even during the most recent period. Our results do not favor the hypothesis of premature aging in HIV patients for KS and cervical cancer. Among treated patients with immunological (i.e. CD4 count ≥500/mm 3 during at least two years) and virological success, the risk was not increased for NHL but remained higher than in the general population for KS. This suggest that cART would be most A c c e p t e d M a n u s c r i p t 24 Age at cancer diagnosis is presented as the median (Inter-Quartile Range).
*Real difference estimated as the difference between observed age at cancer diagnosis in the HIV-infected population and expected age at cancer diagnosis in the general population.
**P value for the comparison of median age for cancers observed in people with HIV and expected cases in the general population.
Expected cases are adjusted for age and sex. by Jules Levin on August 13, 2013 
